Innoviva (INVA) Revenue & Revenue Breakdown
Innoviva Revenue Highlights
Latest Revenue (Y)
$310.46M
Latest Revenue (Q)
$99.90M
Main Segment (Y)
Royalty
Innoviva Revenue by Period
Innoviva Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $310.46M | -6.30% |
| 2022-12-31 | $331.34M | -15.45% |
| 2021-12-31 | $391.87M | 16.35% |
| 2020-12-31 | $336.79M | 29.03% |
| 2019-12-31 | $261.02M | 0.00% |
| 2018-12-31 | $261.00M | 20.16% |
| 2017-12-31 | $217.22M | 62.63% |
| 2016-12-31 | $133.57M | 147.58% |
| 2015-12-31 | $53.95M | 539.74% |
| 2014-12-31 | $8.43M | 77.24% |
| 2013-12-31 | $4.76M | -96.50% |
| 2012-12-31 | $135.76M | 453.84% |
| 2011-12-31 | $24.51M | 1.19% |
| 2010-12-31 | $24.22M | -0.62% |
| 2009-12-31 | $24.37M | 5.53% |
| 2008-12-31 | $23.10M | 4.97% |
| 2007-12-31 | $22.00M | 12.33% |
| 2006-12-31 | $19.59M | 62.49% |
| 2005-12-31 | $12.05M | 34.83% |
| 2004-12-31 | $8.94M | 147.99% |
| 2003-12-31 | $3.60M | 2210.90% |
| 2002-12-31 | $156.00K | 100.00% |
| 2001-12-31 | - | 100.00% |
| 2000-12-31 | - | - |
Innoviva generated $310.46M in revenue during NA 2023, up -6.30% compared to the previous quarter, and up 118.95% compared to the same period a year ago.
Innoviva Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $99.90M | 23.40% |
| 2024-03-31 | $80.95M | -9.32% |
| 2023-12-31 | $89.27M | 32.73% |
| 2023-09-30 | $67.26M | -16.96% |
| 2023-06-30 | $80.99M | 6.05% |
| 2023-03-31 | $76.37M | 16.06% |
| 2022-12-31 | $65.80M | -2.16% |
| 2022-09-30 | $67.26M | -37.85% |
| 2022-06-30 | $108.22M | 20.17% |
| 2022-03-31 | $90.06M | -16.36% |
| 2021-12-31 | $107.68M | 10.03% |
| 2021-09-30 | $97.86M | -2.92% |
| 2021-06-30 | $100.81M | 17.88% |
| 2021-03-31 | $85.52M | -5.48% |
| 2020-12-31 | $90.48M | 2.01% |
| 2020-09-30 | $88.69M | 12.35% |
| 2020-06-30 | $78.95M | 0.34% |
| 2020-03-31 | $78.68M | 3.56% |
| 2019-12-31 | $75.97M | 15.54% |
| 2019-09-30 | $65.75M | 2.57% |
| 2019-06-30 | $64.11M | 16.17% |
| 2019-03-31 | $55.18M | -30.90% |
| 2018-12-31 | $79.86M | 29.47% |
| 2018-09-30 | $61.68M | -8.06% |
| 2018-06-30 | $67.09M | 28.08% |
| 2018-03-31 | $52.38M | -24.65% |
| 2017-12-31 | $69.52M | 42.92% |
| 2017-09-30 | $48.64M | -16.94% |
| 2017-06-30 | $58.56M | 44.63% |
| 2017-03-31 | $40.49M | -7.15% |
| 2016-12-31 | $43.61M | 30.93% |
| 2016-09-30 | $33.31M | 2.58% |
| 2016-06-30 | $32.47M | 34.32% |
| 2016-03-31 | $24.18M | 5.87% |
| 2015-12-31 | $22.84M | 68.38% |
| 2015-09-30 | $13.56M | 27.28% |
| 2015-06-30 | $10.65M | 54.51% |
| 2015-03-31 | $6.90M | -5.27% |
| 2014-12-31 | $7.28M | 628.73% |
| 2014-09-30 | $999.00K | 6.96% |
| 2014-06-30 | $934.00K | 466.06% |
| 2014-03-31 | $165.00K | -89.99% |
| 2013-12-31 | $1.65M | 275.40% |
| 2013-09-30 | $439.00K | -66.92% |
| 2013-06-30 | $1.33M | -1.26% |
| 2013-03-31 | $1.34M | -76.82% |
| 2012-12-31 | $5.80M | 305.45% |
| 2012-09-30 | $1.43M | - |
| 2012-06-30 | $1.43M | -98.87% |
| 2012-03-31 | $127.10M | 2270.37% |
| 2011-12-31 | $5.36M | -16.62% |
| 2011-09-30 | $6.43M | 0.66% |
| 2011-06-30 | $6.39M | 0.92% |
| 2011-03-31 | $6.33M | -8.80% |
| 2010-12-31 | $6.94M | 30.93% |
| 2010-09-30 | $5.30M | -15.36% |
| 2010-06-30 | $6.26M | 9.63% |
| 2010-03-31 | $5.71M | 49.50% |
| 2009-12-31 | $3.82M | -30.70% |
| 2009-09-30 | $5.51M | 0.40% |
| 2009-06-30 | $5.49M | -42.45% |
| 2009-03-31 | $9.54M | 60.48% |
| 2008-12-31 | $5.95M | -0.87% |
| 2008-09-30 | $6.00M | 8.97% |
| 2008-06-30 | $5.50M | -2.48% |
| 2008-03-31 | $5.64M | 0.27% |
| 2007-12-31 | $5.63M | - |
Innoviva generated $99.90M in revenue during Q2 2024, up 23.40% compared to the previous quarter, and up 130.80% compared to the same period a year ago.
Innoviva Revenue Breakdown
Innoviva Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 20 |
|---|---|---|---|
| Royalty | $238.85M | $311.64M | $73.09M |
| License | $1.60M | - | - |
| License Revenue | $11.00M | - | - |
| Product | $60.62M | $19.69M | - |
| Collaborative Arrangements | - | - | $10.00M |
Innoviva's latest annual revenue breakdown by segment (product or service), as of Dec 23: Royalty (76.54%), Product (19.42%), License Revenue (3.52%), and License (0.51%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalty | $63.74M | $58.41M | $66.17M | $53.56M | $62.27M | $56.86M | $51.22M | $42.72M | $29.31M | $35.59M | $26.39M | - |
| Product | $21.65M | $19.08M | $19.68M | $13.70M | $15.73M | $11.51M | $14.59M | $5.11M | - | - | - | - |
| License Revenue | $14.51M | - | - | - | $3.00M | $8.00M | - | - | - | - | - | - |
| License | - | - | - | $1.60M | - | - | - | - | - | - | - | - |
Innoviva's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Royalty (63.81%), Product (21.67%), and License Revenue (14.52%).
Innoviva Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| INCY | Incyte | $3.70B | $1.04B |
| ARGX | argenx SE | $1.23B | $401.00M |
| HRMY | Harmony Biosciences | $582.02M | $172.81M |
| FOLD | Amicus Therapeutics | $399.36M | $110.40M |
| AMLX | Amylyx Pharmaceuticals | $380.79M | $88.64M |
| APLS | Apellis Pharmaceuticals | $366.28M | $179.14M |
| DNLI | Denali Therapeutics | $330.53M | - |
| INVA | Innoviva | $310.46M | $99.90M |
| HOOK | HOOKIPA Pharma | $20.13M | - |
| LIFE | aTyr Pharma | $353.00K | $235.00K |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| PDSB | PDS Bio | - | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| ELEV | Elevation Oncology | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| EFTR | eFFECTOR Therapeutics | - | - |
INVA Revenue FAQ
What is Innoviva’s yearly revenue?
Innoviva's yearly revenue for 2023 was $310.46M, representing a decrease of -6.30% compared to 2022. The company's yearly revenue for 2022 was $331.34M, representing a decrease of -15.45% compared to 2021. INVA's yearly revenue for 2021 was $391.87M, representing an increase of 16.35% compared to 2020.
What is Innoviva’s quarterly revenue?
Innoviva's quarterly revenue for Q2 2024 was $99.9M, a 23.40% increase from the previous quarter (Q1 2024), and a 23.34% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $80.96M, a -9.32% decrease from the previous quarter (Q4 2023), and a 6.00% increase year-over-year (Q1 2023). INVA's quarterly revenue for Q4 2023 was $89.27M, a 32.73% increase from the previous quarter (Q3 2023), and a 35.67% increase year-over-year (Q4 2022).
What is Innoviva’s revenue growth rate?
Innoviva's revenue growth rate for the last 3 years (2021-2023) was -20.77%, and for the last 5 years (2019-2023) was 18.94%.
What are Innoviva’s revenue streams?
Innoviva's revenue streams in c 23 are Royalty, License, License Revenue, and Product. Royalty generated $238.85M in revenue, accounting 76.54% of the company's total revenue, down -23.36% year-over-year. License generated $1.6M in revenue, accounting 0.51% of the company's total revenue License Revenue generated $11M in revenue, accounting 3.52% of the company's total revenue Product generated $60.62M in revenue, accounting 19.42% of the company's total revenue, up 207.79% year-over-year.
What is Innoviva’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Innoviva was Royalty. This segment made a revenue of $238.85M, representing 76.54% of the company's total revenue.